Pyramid Analytics Appoints Tom Warren as Regional Managing Director, UK & Ireland
BIG DATA ANALYTICS CONFERENCE – Pyramid Analytics (Pyramid), a pioneering decision intelligence platform provider, announced today that Tom Warren has been appointed Regional Managing Director, UK and Ireland (UKI). Warren brings with him twelve years of experience leading high achieving teams, alongside his previous experience as a professional rugby player, to build upon Pyramid’s growth in the UKI. The company’s customers in the UKI include Ann Summers, Liberty London, and Premier Foods.
The appointment follows Pyramid Analytics’ recent oversubscribed US $120MM Series E funding round, which was announced at a special event on May 9 from Tower Bridge in London. Pyramid is doubling down on its investment in the UKI, a leading market for decision intelligence adoption. In 2022, the UK tech ecosystem hit a landmark valuation of $1 trillion. At the centre of this tech success story is London. Pyramid plans to double its headcount in London over the coming months, to then use London as a base to support its European expansion. The appointment of Warren highlights Pyramid’s commitment to, and ambitions for, the UK and Ireland.
Key Points:
- Pyramid Analytics, a decision intelligence platform provider, hires experienced technology sector leader Tom Warren to accelerate UKI growth. Warren has twelve years leading successful teams and customer relationship management.
- Pyramid expanding investment in UKI talent, sales and marketing, and partner expansion.
- Warren’s appointment is the first in a series of planned business development initiatives to support customer success and strategic accounts in this region.
- Click here to schedule a demo of the Pyramid Decision Intelligence Platform.
Warren’s remit is to build out the UK and Ireland business, which will involve enterprise sales, business development, and channel and solutions engineering functions. Having started his career as a professional rugby player, Tom Warren is excited about the challenge ahead.
Meet our new Managing Director
Warren had a successful career as a professional rugby player for Worcester Warriors, London Irish, Grand Parma in Italy and finally at Esher RFC. This included a Division 1 title for Worcester in 2004 and playing in an English Premiership semi-final and European Challenge Cup final for London Irish in 2006. After his retirement, Warren initially turned his hand to coaching as the Scrum Coach and Director of the Academy at Esher.
Since then, he has had a successful career in sales. His most recent role was as Area VP Northern Europe at the cloud-based logistics platform Bringg where he was responsible for building out the EMEA sales team. In a previous role as Senior Director for EMEA Enterprise renewals at Blue Prism, he successfully increased customer renewals from 82% to 88%, which accounted for a 113% increase in the 2019 financial year. He was also Regional Sales Director at ServiceNow, where he set up the first UK Commercial sales team and consistently exceeded targets for delivering new business to help grow the UK business.
Decision Intelligence is the Next Big Data Analytics Innovation
The next major innovation in analytics is Artificial Intelligence (AI). Applying AI across Data Prep, Business Analytics, and Data Science is what separates Decision Intelligence from traditional business intelligence tools such as Microsoft Power BI, Qlik, and Tableau. AI lowers the skills barrier by automating the highly technical work needed to prepare and analyze data and create and share reports and dashboards.
The Pyramid Decision Intelligence Platform delivers data-driven insights for anyone to make faster, more intelligent decisions. The Pyramid Platform provides instant access to any data, enables automated governed self-service for any person, and serves any analytics need, from the simple to the sophisticated. By uniquely combining Data Prep, Business Analytics, and Data Science with AI guidance in a single environment, the Pyramid Platform reduces cost and complexity while accelerating growth and innovation. This enables a strategic, organization-wide approach to Business Intelligence and Analytics.
Quotes
Omri Kohl, Chief Executive Officer and Co-Founder, Pyramid Analytics: “Tom has brought a vast wealth of expertise and insight to the Managing Director role. He has a strong history of leading impressively successful sales and customer relationship teams and has helped multiple companies expand their sales outreach into the EMEA region.
“As a former professional rugby player and with over twelve years of heading sales teams, we knew that Tom would bring strong leadership skills, courage and energy to our growing team here at Pyramid. We believe that Tom is the right individual to lead our already high performing team to continue our growth in the UK and Ireland, following our phenomenal Series E funding round performance.”
Tom Warren , Regional Managing Director, UKI, Pyramid Analytics: “Pyramid is what’s next in analytics and the UK is what’s next for Pyramid. I am really excited to be joining Pyramid Analytics and even more so to be joining a successful and high performing team, which has been behind their expansion in the UK and Ireland.
“Our Series E funding round earlier this month was a real statement of intent from the company, showcasing our ambition to expand our UK and Ireland operations so that Decision Intelligence can continue to transform the way businesses operate in the region. I look forward to contributing to this great company and working towards our European expansion.”
About Pyramid Analytics
Pyramid is what’s next in analytics. Our unified decision intelligence platform delivers insights for everyone to make faster, more informed decisions. It provides direct access to any data, enables governed self-service for any person, and serves any analytics need in a no-code environment. Decision Intelligence Platform uniquely combines Data Prep, Business Analytics, and Data Science in a single environment with AI guidance, reducing cost and complexity while accelerating growth and innovation. The Pyramid Platform enables a strategic, organization-wide approach to Business Intelligence and Analytics, from the simple to the sophisticated. Schedule a demo.
Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel-Aviv. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Investors include H.I.G. Growth Partners, Jerusalem Venture Partners (JVP), Sequoia Capital, and Viola Growth. Learn more at Pyramid Analytics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220616005248/en/
Contact information
Media contacts:
UK
Susie Evershed
Resonance
+44 7966 145092
pyramidanalytics@resonancecrowd.com
US
Heather Racicot
Resonance
+1 360-632-5616
pyramidanalytics@resonancecrowd.com
Chas Kielt
Vice President of Global Corporate Communications and Partner Marketing, Pyramid Analytics
617.687.3371
chas.kielt@pyramidanalytics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
